68Ga-PSMA-11 PET/CT in a patient with non-PSA-secreting undifferentiated prostate cancer before and after treatment with cabozantinib

  • Carlos ArtigasEmail author
  • N. Plouznikoff
  • T. Gil
  • I. Duran Derijckere
  • M. Herchuelz
  • I. Libert
  • P. Flamen
Image of the Month
Part of the following topical collections:
  1. Image of the month


Compliance with ethical standards

Following the patient’s death, consent for publication was obtained from his immediate family.

Conflicts of interests



  1. 1.
    Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.CrossRefGoogle Scholar
  2. 2.
    Basch EM, Scholz M, de Bono JS, Vogelzang N, de Souza P, Marx G, et al. Cabozantinib versus mitoxantrone-prednisone in symptomatic metastatic castration-resistant prostate cancer: a randomized phase 3 trial with a primary pain endpoint. Eur Urol. 2019;75:929–37.CrossRefGoogle Scholar
  3. 3.
    Lee DK, Park JH, Kim JH, Lee SJ, Jo MK, Gil MC, et al. Progression of prostate cancer despite an extremely low serum level of prostate-specific antigen. Korean J Urol. 2010;51:358–61.CrossRefGoogle Scholar
  4. 4.
    Artigas C, Alexiou J, Garcia C, Wimana Z, Otte FX, Gil T, et al. Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:195–6.CrossRefGoogle Scholar
  5. 5.
    Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, et al. The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. Eur J Nucl Med Mol Imaging. 2017;44(5):788–800.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Nuclear MedicineInstitut Jules Bordet, Université Libre de Bruxelles (ULB)BrusselsBelgium
  2. 2.Department of Nuclear MedicineCentre Hospitalier de l’Université de Montréal (CHUM)MontrealCanada
  3. 3.Department of OncologyInstitut Jules Bordet, Université Libre de Bruxelles (ULB)BrusselsBelgium
  4. 4.Department of Palliative and Supportive CareInstitut Jules Bordet, Université Libre de Bruxelles (ULB)BrusselsBelgium

Personalised recommendations